Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Adjuvant therapy of gastrointestinal stromal tumors.

Koshenkov VP, Rodgers SE.

Curr Opin Oncol. 2012 Jul;24(4):414-8. doi: 10.1097/CCO.0b013e328353d774. Review.

PMID:
22572723
2.

Optimizing tyrosine kinase inhibitor therapy in gastrointestinal stromal tumors: exploring the benefits of continuous kinase suppression.

Le Cesne A, Blay JY, Reichardt P, Joensuu H.

Oncologist. 2013;18(11):1192-9. doi: 10.1634/theoncologist.2012-0361. Review.

3.
4.

Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors.

Nishida T, Doi T, Naito Y.

Expert Opin Pharmacother. 2014 Oct;15(14):1979-89. doi: 10.1517/14656566.2014.937707. Review.

PMID:
24990162
5.

Downsizing treatment with tyrosine kinase inhibitors in patients with advanced gastrointestinal stromal tumors improved resectability.

Sjölund K, Andersson A, Nilsson E, Nilsson O, Ahlman H, Nilsson B.

World J Surg. 2010 Sep;34(9):2090-7. doi: 10.1007/s00268-010-0639-5.

6.

Adjuvant therapy for high-risk gastrointestinal stromal tumour: considerations for optimal management.

Joensuu H.

Drugs. 2012 Oct 22;72(15):1953-63. doi: 10.2165/11635590-000000000-00000.

PMID:
22994537
7.

Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib: A retrospective analysis.

Montemurro M, Gelderblom H, Bitz U, Schütte J, Blay JY, Joensuu H, Trent J, Bauer S, Rutkowski P, Duffaud F, Pink D.

Eur J Cancer. 2013 Mar;49(5):1027-31. doi: 10.1016/j.ejca.2012.10.009.

PMID:
23140824
8.

A decade of tyrosine kinase inhibitor therapy: Historical and current perspectives on targeted therapy for GIST.

Blay JY.

Cancer Treat Rev. 2011 Aug;37(5):373-84. doi: 10.1016/j.ctrv.2010.11.003. Review.

PMID:
21195552
9.

Imatinib escalation or sunitinib treatment after first-line imatinib in metastatic gastrointestinal stromal tumor patients.

Hsu CC, Wu CE, Chen JS, Tseng JH, Chiang KC, Liu YY, Tsai CY, Cheng CT, Chen TW, Jan YY, Yeh TS, Chen YY, Yeh CN.

Anticancer Res. 2014 Sep;34(9):5029-36.

PMID:
25202087
10.

Efficacy and safety of sunitinib in Chinese patients with imatinib-resistant or -intolerant gastrointestinal stromal tumors.

Li J, Gao J, Hong J, Shen L.

Future Oncol. 2012 May;8(5):617-24. doi: 10.2217/fon.12.29.

PMID:
22646775
11.

Second line therapies for the treatment of gastrointestinal stromal tumor.

Joensuu H.

Curr Opin Oncol. 2007 Jul;19(4):353-8. Review.

PMID:
17545799
12.

Management of localized gastrointestinal stromal tumors and adjuvant therapy with imatinib.

López RL, del Muro XG.

Anticancer Drugs. 2012 Jun;23 Suppl:S3-6. doi: 10.1097/CAD.0b013e3283559fab. Review.

PMID:
22739667
13.

Adjuvant therapy in primary GIST: state-of-the-art.

Reichardt P, Blay JY, Boukovinas I, Brodowicz T, Broto JM, Casali PG, Decatris M, Eriksson M, Gelderblom H, Kosmidis P, Le Cesne A, Pousa AL, Schlemmer M, Verweij J, Joensuu H.

Ann Oncol. 2012 Nov;23(11):2776-81. doi: 10.1093/annonc/mds198. Review.

14.

The role of KIT in the management of patients with gastrointestinal stromal tumors.

Hornick JL, Fletcher CD.

Hum Pathol. 2007 May;38(5):679-87. Review.

PMID:
17437861
15.

Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial.

Kang YK, Ryu MH, Yoo C, Ryoo BY, Kim HJ, Lee JJ, Nam BH, Ramaiya N, Jagannathan J, Demetri GD.

Lancet Oncol. 2013 Nov;14(12):1175-82. doi: 10.1016/S1470-2045(13)70453-4.

16.

Managing progressive disease in patients with GIST: factors to consider besides acquired secondary tyrosine kinase inhibitor resistance.

Patel S.

Cancer Treat Rev. 2012 Aug;38(5):467-72. doi: 10.1016/j.ctrv.2011.10.001. Review.

PMID:
22035971
17.

Current management of gastrointestinal stromal tumors--a comprehensive review.

Lai EC, Lau SH, Lau WY.

Int J Surg. 2012;10(7):334-40. doi: 10.1016/j.ijsu.2012.05.007. Review.

18.

One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.

Joensuu H, Eriksson M, Sundby Hall K, Hartmann JT, Pink D, Schütte J, Ramadori G, Hohenberger P, Duyster J, Al-Batran SE, Schlemmer M, Bauer S, Wardelmann E, Sarlomo-Rikala M, Nilsson B, Sihto H, Monge OR, Bono P, Kallio R, Vehtari A, Leinonen M, Alvegård T, Reichardt P.

JAMA. 2012 Mar 28;307(12):1265-72. doi: 10.1001/jama.2012.347.

PMID:
22453568
19.

Cost effectiveness of tyrosine kinase inhibitor therapy in metastatic gastrointestinal stromal tumors.

Blanke CD, Huse DM.

J Med Econ. 2010;13(4):681-90. doi: 10.3111/13696998.2010.534670. Review.

PMID:
21067355
20.

Surgical intervention for imatinib and sunitinib-resistant gastrointestinal stromal tumors.

Kikuchi H, Setoguchi T, Miyazaki S, Yamamoto M, Ohta M, Kamiya K, Sakaguchi T, Konno H.

Int J Clin Oncol. 2011 Dec;16(6):741-5. doi: 10.1007/s10147-011-0208-4.

PMID:
21394667
Items per page

Supplemental Content

Support Center